Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 27Burkitt Lymphoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Leukemia, Biphenotypic, Acute 5Leukemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Myelodysplastic Syndromes 2Leukemia, Monocytic, Acute 2Thrombocythemia, Essential 1Sarcoma, Myeloid 1Primary Myelofibrosis 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasms 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Basophilic, Acute 1Hematologic Neoplasms 1Down Syndrome 1Acute Myeloid Leukemia With KMT2A Rearrangement 1

Interventions

ruxolitinib 9fludarabine phosphate 8fludarabine 8Whole-Body Irradiation 8Specimen Handling 7Cytarabine 7Cyclophosphamide 7Mycophenolic Acid 6Tacrolimus 5Injections 5Busulfan 5Biopsy 5Azacitidine 5Stem Cell Transplantation 4Sirolimus 4Peripheral Blood Stem Cell Transplantation 4Melphalan 4Granulocyte Colony-Stimulating Factor 4CPX-351 4venetoclax 3luspatercept 3decitabine and cedazuridine drug combination 3Liposomes 3Idarubicin 3Daunorubicin 3Cyclosporine 3Blood Specimen Collection 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3selinexor 2nilotinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × Daunorubicin × 90 days × Clear all
NCT05554406 2026-06-05

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
335 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT05564390 2026-06-05

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Recruiting
2,000 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT03878199 2026-04-24

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

Ohio State University Comprehensive Cancer Center

Phase 1/2 Terminated
12 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡